BeOne Medicines Ltd. shares fall 3.20% premarket after BeiGene's EU approval of Tevimbra combo for lung cancer.

Beone Medicines Ltd. declined 3.20% in premarket trading. The company announced that the European Commission has approved TEVIMBRA (tislelizumab) in combination with platinum-containing chemotherapy as neoadjuvant treatment followed by TEVIMBRA monotherapy as adjuvant treatment, for adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. The approval is based on results from the Phase 3 RATIONALE-315 trial, which demonstrated statistically significant and clinically meaningful benefit in overall survival (OS) compared to placebo.